Key Points
- CEO Daniel Faga sold 17,679 shares on March 27 at an average $61.61 for about $1.09 million, reducing his stake by roughly 3.44% and continuing a string of insider sales earlier in January.
- Board authorized a $100 million share repurchase and approved the spin‑off of First Tracks Biotherapeutics (expected to trade as TRAX on April 20, 2026), with the spin‑out securing about $145 million in private placement commitments.
- Shares traded lower (~11.7% intraday) despite a strong quarter (EPS $1.58 vs. $0.89 est., revenue $108.3M vs. $87.1M); analysts maintain a generally bullish view with an average target near $78 and some price targets as high as $90.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CEO Daniel Faga sold 17,679 shares of the firm's stock in a transaction that occurred on Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the sale, the chief executive officer owned 495,965 shares in the company, valued at $30,556,403.65. This represents a 3.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Daniel Faga also recently made the following trade(s):
- On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The stock was sold at an average price of $44.71, for a total value of $638,503.51.
- On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total value of $415,102.22.
- On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total transaction of $662,267.34.
AnaptysBio Stock Down 11.7%
NASDAQ ANAB opened at $57.40 on Friday. AnaptysBio, Inc. has a twelve month low of $15.40 and a twelve month high of $68.39. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -110.38 and a beta of 0.32. The stock has a fifty day simple moving average of $55.30 and a 200 day simple moving average of $43.64.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The company had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. Research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.
AnaptysBio declared that its board has initiated a stock repurchase plan on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.
Analysts Set New Price Targets
Several brokerages recently issued reports on ANAB. Wall Street Zen lowered shares of AnaptysBio from a "strong-buy" rating to a "buy" rating in a research note on Friday, January 23rd. UBS Group increased their price target on AnaptysBio from $70.00 to $90.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Guggenheim reissued a "buy" rating on shares of AnaptysBio in a research report on Thursday, December 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Truist Financial upgraded AnaptysBio to a "hold" rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $78.44.
Check Out Our Latest Analysis on ANAB
Trending Headlines about AnaptysBio
Here are the key news stories impacting AnaptysBio this week:
- Positive Sentiment: Analyst price target raised ~21% to $79.82, signaling stronger analyst expectations for the stock’s upside. Read More.
- Positive Sentiment: Truist upgraded the stock, reinforcing the bullish analyst view alongside the higher price target and potentially supporting future buying interest. Read More.
- Positive Sentiment: Board authorized a $100 million stock repurchase program — a capital-return move that typically reduces float and signals management’s view that shares are undervalued. Read More.
- Positive Sentiment: Board approved the previously announced spin‑off of First Tracks Biotherapeutics; the new company is expected to begin trading as TRAX on Nasdaq on April 20, 2026 — a structural change that can unlock value if investors assign separate valuations. Read More.
- Positive Sentiment: First Tracks secured commitments of $145 million in a private placement, which should fund the spin‑out’s initial operations and reduce execution risk for the new company. Read More.
- Neutral Sentiment: The company provided a business update alongside the repurchase/spin‑off announcements; details strengthen the strategic narrative but will be judged on execution. Read More.
- Negative Sentiment: CEO Daniel Faga sold 17,679 shares (≈$1.09M) at an average $61.61 on March 27, reducing his stake ~3.44%; insider sales can trigger investor caution and may have contributed to intraday selling pressure. Read More. Read More.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Federated Hermes Inc. boosted its stake in AnaptysBio by 2,236.6% during the third quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company's stock valued at $5,920,000 after buying an additional 185,053 shares during the period. Panagora Asset Management Inc. purchased a new position in shares of AnaptysBio during the second quarter worth approximately $741,000. Assenagon Asset Management S.A. raised its position in AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company's stock worth $25,719,000 after purchasing an additional 822,975 shares during the period. 683 Capital Management LLC lifted its stake in shares of AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company's stock valued at $11,100,000 after acquiring an additional 304,373 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in AnaptysBio in the second quarter valued at approximately $680,000.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
